RCE obviously has trade secrets, other Companies are trying emulate the novel cure development process.
I said the pathogen/s RCE is targeting is like a scaffold inside the scaffold is a an electrical switch box which R327 turns off. It does this by turning off the switch by a lock and key method as this part of the electrical box is not protected by the SlmA protein. This alters the chromosome thus negating replication. The pathogen is normally protected by SlmA as a coating but not this particular area.
Ok, how does it do this . The synthetic polymer anti biotic R327 uses molecular weight ( small molecule) , polymer architecture ( key to get in to the electrical box) , cationic arm ( an electrical charge that is attracted to the pathogen ) and low level lipophicity ( which means it dissolves in the pathogen/s outer membrane cell).
It is well known that bugs create super bugs that are resistant to anti biotics. This is due to the outer cell wall permeability strengthens due to mutations of the pathogen due to the current old and tried anti biotics not killing all of the pathogen.
Finally, R327 is targeting particular pathogens which fit the above. Not all pathogens have the same structural set up.
Having done my due diligence in the Company and I see NZT ( he is a good barometer) is in, I have invested.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)